🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

127 results for “Jin” Clear

  1. Delamanid

    Otsuka Beijing Research Institute

    Tuberculosis, Multidrug-Resistant

    phase 2 small molecule completed

    1 trial

  2. Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 2 small molecule completed

    1 trial

  3. Dimethyl fumarate

    Xuanwu Hospital, Beijing

    Intracerebral Hemorrhage

    phase 2 small molecule terminated

    1 trial

  4. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  5. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. JNT-517 Suspension

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 2 small molecule completed

    1 trial

  8. Jintrolong® low dose group

    The First People's Hospital of Lianyungang

    Dwarfism

    phase 2 small molecule active

    1 trial

  9. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  10. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  11. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  12. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  13. Prednisone

    Nanjing Children's Hospital

    Henoch-Schoenlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  14. Rezvilutamide

    Nanjing Zenshine Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  15. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  16. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial

  17. TwHF

    Beijing 302 Hospital

    Human Immunodeficiency Virus

    phase 2 small molecule active

    1 trial

  18. low-dose lymphocyte immunotherapy

    Nanjing Zenshine Pharmaceuticals

    Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

    phase 2 other completed

    1 trial

  19. 100 mg Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 1 small molecule completed

    1 trial

  20. A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

    Otsuka Beijing Research Institute

    Tuberculosis

    phase 1 other active

    1 trial

  21. A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

    Otsuka Beijing Research Institute

    Incomplete Response - Major Depressive Disorder (IR-MDD)

    phase 1 other active

    1 trial

  22. A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

    Otsuka Beijing Research Institute

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

  23. BCMA/CD19 Dual-Target CAR-T

    Xijing Hospital

    Multiple Myeloma

    phase 1 mab active

    1 trial

  24. BioTTT001 injection

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Locally Advanced Breast Cancer (LABC)

    phase 1 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources